Anixa Biosciences enters partnership to develop additional cancer vaccines

Anixa Biosciences has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer and an ovarian cancer vaccine is in pre-clinical development in collaboration with the National Cancer Institute. The vaccines focus on a novel scientific mechanism never used before in a cancer vaccine. Researchers are investigating if certain cancer cells can be destroyed as they arise, and ultimately prevent tumors from forming. The vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to royalties and other commercialization revenues from the company.